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Background/objective: Follow-up after histologically confirmed normal/CIN1 in cervical 
cancer screening is less studied. The current Norwegian follow-up guideline is combined 
cytology and HPV-testing after six months. The study objective is to examine compliance to 
guidelines and subsequent risk for CIN2+ in this subset of women. 
 
Materials and methods: Women aged 25-69 years in Troms and Finnmark counties 
attending the Norwegian Cervical Cancer Screening Programme were included in this 
registry-based cohort study. An exposed cohort with histologically confirmed normal/CIN1 
after ASC-US/LSIL or ASC-H/HSIL cytologies (N=374) was compared to a control cohort 
having normal cytologies in primary screening (N=25,948). The exposed cohort was stratified 
by the first follow-up cytology being normal or abnormal. Both cohorts were followed up to 
the last time-point of observation of 78 months.  
 
Results: 69.5% of the exposed cohort and 42.2% of the control cohort was compliant to 
guidelines. The 42-month cumulative incidence of CIN2+ was, in the exposed cohort 17.9% 
(abnormal follow-up) and 7.1% (normal follow-up), and 0.43% in the control cohort (p < 
0.01). The 42-month cumulative incidence of CIN3+ was 2.5% (95% CI: 0.0-5.2) in the 
exposed cohort with normal follow-up. Age-adjusted HR for CIN2+ was 22.5 (abnormal 
follow-up) and 9.0 (normal follow-up) (p < 0.01). Women aged 25-39 years had higher 
CIN2+ risks compared to women aged 55-69 years (HR 6.1, p < 0.01). 
 
Conclusion: Compliance to guidelines was better, and the cumulative incidence of CIN2+ 
was significantly higher among women attending follow-up after histologically confirmed 
normal/CIN1 compared to women having normal cytologies in primary screening. The CIN2+ 
risk was higher among younger women. The cumulative incidence of CIN3+ provided by a 
normal follow-up cytology after histologically confirmed normal/CIN1, was closely 
consistent to allow screening in three years. A negative co-test probably provides a risk 





1.1 The Norwegian Cervical Cancer Screening Programme 
Cervical cancer develops over several years through a series of precancerous lesions. Since 
1995, The Norwegian Cervical Cancer Screening Programme (NCCSP) has recommended 
primary screening by cervical cytology every third year for women between 25-69 years. The 
screening programme aims to reduce cervical cancer incidence and mortality by detecting and 
treating premalignant cervical lesions. Age-adjusted incidences of cervical cancer decreased 
by 25 % from 1990-94 to 2000-04, and age-adjusted disease specific mortality decreased by 
34 % during the same period. (1) The organized screening program has shown to be cost 
effective, has increased the screening coverage and has reduced the cervical cancer incidence. 
(2)  
 
1.2 Human Papillomavirus and cervical cancer 
Over the past decades, Human papillomavirus (HPV) has been determined as the causal agent 
for cervical cancer. (3) Cervical HPV-infections cause detectable premalignant lesions in the 
cervical epithelium. Approximately 80 % of sexually active women acquires an infection 
during their lifetime. Most HPV-infections are terminated by the immune system, have a 
mean duration of 6-18 months and most premalignant lesion regress. (4, 5) The variety of 
clinical presentations depend on the oncogenic potential provided by the present HPV-type. 
Thus, there are low- and high-risk groups of HPVs, the former causing condylomas and non-
malignant lesions and the latter causing high grade neoplasia and cancer. (4, 5) 96 % of 
cervical cancer cases are attributed to 13 high risk HPV-types (6) where HPV 16/18/31/33 
and HPV 35/45/52/58 are associated with high and medium risks for high-grade cell dysplasia 
over time, respectively. (7) Presence of HPV in a cervical sample can be confirmed either by 
HPV DNA- or HPV mRNA-tests. HPV mRNA-tests detect HPV E6/E7 mRNA coding for 
oncoproteins that inhibit tumor suppressors and maintain the malignant transformation of 
cervical cancer cells. (5) Thus, HPV mRNA-tests indicate oncogenic viral activity and HPV 





1.3 Cervical cytology and biopsy diagnoses 
The sampling methods performed in most cervical cancer screening programs, including the 
NCCSP, are liquid based cervical cytology (LBC) and biopsies (histology). The methods are 
quite different regarding sampling, morphology and classification.  
 
Liquid based cervical cytology is the most frequent sampling method used for screening. It is 
mostly the only test used in primary screening, but cytology is also used in combination with 
HPV-testing to manage different screening test outcomes. The sampling is performed by 
collecting cells from the ecto- and endocervix using specially designed spatulas and brushes. 
The specimen shows single cell morphologies and any cell abnormalities are classified either 
as atypical squamous cells of undetermined significance (ASC-US), low grade squamous 
intraepithelial lesion (LSIL), atypical squamous cells that cannot exclude high grade lesion 
(ASC-H) or high grade squamous intraepithelial lesion (HSIL). The cytological diagnose 
criteria are mainly based on nuclear morphology (size, number, shape, nuclear/cytoplasm 
ratio, distribution of chromatin, membrane shape etc.). The cytological diagnosis is 
determined by the extensiveness and combination of these criteria. (8, 9)  
 
Only women with histologically confirmed high grade dysplasia are recommended treatment. 
Biopsies are tissue samples collected from the cervix during a colposcopic examination. The 
biopsies are performed either colposcopically guided at visible lesions or from each quadrant 
of the cervix. (9) The biopsies are processed to histological specimens and are evaluated by 
pathologists. Histological specimens show the total tissue composition and any abnormal 
findings are classified as cervical intraepithelial neoplasia (CIN). The CIN grade depends on 
dysplastic distribution within the epithelial layer, for instance differentiation, maturation, 
extent of mitoses and nuclear changes as earlier mentioned. Low grade dysplasia (CIN1) is 
characterized by undifferentiated cells restricted to the basal third of the epithelium. Moderate 
dysplasia (CIN2) show more distinctive nuclear abnormalities in the lower half or two thirds 
of the epithelium. Severe dysplasia (CIN3) is characterized by low differentiation, nuclear 
abnormalities, extensive and abnormal mitoses localized to the whole thickness of the 
epithelium. (10) A biopsy may also show invasive cancer, mostly squamous cell carcinoma 
(SCC) and adenocarcinomas (ACC). (5) High grade dysplasia (CIN2+) is defined as CIN2, 
CIN3 and cancer. According to Norwegian guidelines, women with CIN2+ are recommended 
treatment, usually by conization. 
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1.4 Risk stratification in screening 
Designing suitable follow-up algorithms are challenging for any screening diagnose. The 
purpose of any screening programme is to identify individuals with high risk for severe 
disease. Risk stratification is used to manage the test result follow-up. Castle et. al. (11) 
consider CIN3+ as the best risk indicator for precancer/cancer, because the CIN2 diagnosis is 
poorly reproducible and often indicates an acute HPV-infection. A cumulative incidence of 
CIN3+ (CIN3 and worse) lower than 2.0% is considered as an acceptable threshold to serve as 
basis for the 3-year screening interval recommendation. For CIN3+ risks between 2% and 
10%, the suggested follow-up threshold is within one year. Women having more than 10% 
risk for CIN3+, are recommended immediate referral for colposcopy and biopsy. (11) 
Application of the term “equal management of equal risks” is used to evaluate which 
management that is suitable for cases with similar risk profiles. (12) 
 
1.5 Primary screening test outcome 
According to the NCCSP guidelines, women having normal primary screening results should 
return to screening within three years. Women having high-grade cytology results (ASC-
H/HSIL) are referred to a gynecologist for colposcopy and biopsy. Unsatisfactory test results 
were followed up by new cytology within 6-12 months between 2005-2008 and within 1-3 
months from 2009. (13) 
 
Women with minor cervical lesions (ASC-US/LSIL) are, on the other hand, managed 
differently due to increased risk of CIN3+, though not high enough to recommend immediate 
referral to colposcopy and biopsy. (11, 14) In 2005, HPV-tests were introduced in the 
screening programme, and women with ASC-US/LSIL cytologies in primary screening were 
triaged with HPV and cytology co-testing within 6-12 months (delayed triage). (14)  
 
1.6 ASC-US/LSIL cytology triage 
The NCCSP 2005 guidelines for triage (Figure 1) (15) was valid during the inclusion period 
of this study, and was therefore used as basis to select the study population (see materials and 
methods). Women with triage results of HPV-negative and normal/inadequate/ASC-US/LSIL 
returned to screening. Women with triage results of HPV-positive and ASC-US/LSIL, or 
ASC-H/HSIL regardless of HPV-status, were recommended further examination with 
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colposcopy and biopsy. (14, 15) Women triaged to colposcopy, needed further follow-up or 
treatment, if the biopsy had a histological CIN-diagnosis. 
 
1.7 Histology follow-up 
The current Norwegian follow-up practice of histologically confirmed normal/CIN1 is 
combined cytology and HPV testing after six months. Histologically confirmed CIN2+ is 
normally treated with conization of the cervix. (9)  
 
1.8 Challenges regarding follow-up of histologically confirmed 
normal/CIN1 
The distribution of histological diagnoses has changed since introduction of HPV-testing and 
ASC-US/LSIL triage in several screening programs, and is possibly explained by additional 
low-risk women being eligible for colposcopy and biopsy. (16, 17) In Norway, the mean 
CIN1 fraction of all histology diagnoses has showed an increasing trend; 6.7% (2009), 7.14% 
(2012) and 9.0% (2014). (18-20) The sensitivity for detecting CIN2+ lesions at colposcopy 
has been reported as 39% (21) and 66.2% (22), suggesting that suspected high-grade lesions 
cannot be ruled out even if a woman is diagnosed with a histologically confirmed low-grade 
lesion. (22) There are significant interpretive variations among pathologists for 
histopathological cervical specimens (23), and there are few definitive methods yet, that help 
identify cases in high risk for progression. p16 immunostaining is a frequently used biomarker 
for this purpose, suggestively indicated to evaluate uncertain dysplasia present on 
conventional hematoxylin-eosin (HE)-stains, or for negative HE-stains together with positive 
HPV-tests or antecedent high-grade cytology results. (24) The HPV test-type used has been 
reported to influence the colposcopy referral rate, being 57 % higher for HPV DNA-tests 
compared to HPV mRNA-tests. (25)  
 
Studies have shown that 50-70% of CIN1 lesions spontaneously regress within 12 months and 
only 4% and 7% progress to CIN2+ within six and 12 months, respectively. (26, 27) 
According to Castle et al. (28) the CIN1 diagnosis itself is not a significant risk factor for 
CIN3 above the risk attributed to the genotype specific HPV-infection. Sørbye et al (29) 




Several factors challenge the normal/CIN1 histology management. A complex follow-up 
algorithm may lead to decreased compliance and psychological distress. By conservative 
follow-up, 9-16 % develop CIN2-3, suggesting similar management as for an ASC-US/LSIL 
cytology. (30) A triage test with high specificity may reduce the number of unnecessary 
referrals. (25, 31) 
 
1.9 Relevant literature on CIN2+ risks after histologically 
confirmed normal/CIN1 
 
The CIN2+ risk among women having histologically confirmed normal/CIN1, has shown to 
be influenced by their antecedent cytology and/or HPV-test result. Katki et. al. (17) reported 
that women who had an antecedent ASC-US/LSIL cytology and who were HPV-positive, had 
a lower 5-year risk for CIN2+ (10%) than for antecedent ASC-H (16%) or HSIL (24%). They 
examined the CIN2+ risks in follow-up by different combinations of negative HPV-tests and 
negative cytology results (co-test negative, HPV-negative or cytology negative). In this subset 
of women, the lowest 5-year CIN2+ risk of 1.1% and 2.2% was provided by one negative co-
test for antecedent HPV-positive/ASC-US/LSIL and antecedent ASC-H/HSIL, respectively. 
The negative co-test among antecedent ASC-US/LSIL and HPV-positive women, provided a 
CIN2+ risk consistent to follow-up within three years. 
 
Guido et. al. (32) compared follow-up of women having CIN1 or less on immediate 
colposcopy and biopsy after HPV-positive ASC-US or LSIL, in the ASC-US LSIL Triage 
Study (ALTS). They reported the CIN2/3 risk to be 9.8% and 11.3%, respectively.  
 
Mittal et. al. (33) assessed the CIN2+ risk and associated risk factors in follow-up of high-risk 
HPV (HR-HPV) positive women having histologically confirmed normal/CIN1, in a public 
screening demonstration project in rural areas in India. In this subset of women, 6.3% 
progressed to CIN2+, and the only significant factor was HPV-persistence.  
 
1.10 Study objective 
There are few studies investigating the histologically confirmed normal/CIN1 follow-up in a 
screening scenario. The objective of this study is to examine guideline compliance and CIN2+ 
risks among women with histologically confirmed normal/CIN1, compared to a control 
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cohort. Which cytology and HPV-test outcomes, alone or in combination, provides the lowest 




2 Materials and methods 
 
2.1 Study design and data 
This study is a prospectively designed registry-based cohort study of an exposed cohort 
compared to a non-exposed control cohort. The data is obtained from a database containing 
cervical cancer screening data from the Department of Clinical Pathology, University 
Hospital of Northern Norway (UNN). 
 
2.2 Defining the exposed cohort, control cohort and index 
sample 
The exposed cohort (study population) is defined as women having histologically confirmed 
normal/CIN1 (exposed cohort index). The non-exposed cohort (control cohort) is defined as 
women having a normal inclusion cytology (control cohort index). 
 
2.3 Defining the inclusion cytology  
The inclusion cytology is restricted to women who had at least one cytology analyzed at the 
Department of Clinical Pathology, UNN, for the exposed cohort within January 1, 2006 
through December 31, 2011 and for the control cohort within January 1, 2006 through 
December 31, 2007. The inclusion cytology result determined cohort allocation. The exposed 
cohort comprised women having ASC-US/LSIL (eligible for triage) or ASC-H/HSIL (eligible 
for immediate biopsy) inclusion cytologies. The control cohort comprised women with a 




2.4 Exclusion criteria 
After identifying all women eligible for study participation, we excluded non-residents of the 
Troms and Finnmark counties, women outside screening age (≤ 24 years and ≥ 70 years) and 
women who had a history of high grade cervical cytology (≥ HSIL) and/or high-grade 
histology (≥ CIN1).  
 
Further exclusion was restricted to women in the exposed cohort, who either underwent ASC-
US/LSIL triage (Figure 1) or had immediate colposcopy and biopsy (inclusion ASC-H/HSIL). 
We excluded women missing follow-up, women returning to screening (HPV negative ASC-
US/LSIL or normal cytology), women having incomplete follow-up (not according to 
management guidelines or case unsolved) and women having high-grade cervical lesions or 
cancer (CIN2+).  
 
2.5 Follow-up and endpoint  
Both cohorts were followed up from the time of their respective index samples, through 
December 31, 2014 (study end). Histologically confirmed CIN2+ was considered as endpoint 
of disease. Risk calculations were in the exposed cohort stratified by the first follow-up 
cytology being normal or abnormal (inadequate, ASC-US+). Cervical cancer was classified 
according to The International Federation of Gynecology and Obstetrics (FIGO) classification 
system. (9) 
 
2.6 Compliance to follow-up and first screening round 
Women in the exposed cohort were recommended follow-up within 6-12 months. Compliance 
to follow-up was considered as within interval if < 12 months and as late if > 13 months. 
Women in the control cohort were recommended screening in three years. Compliance to 
follow-up was considered as early if < 23 months, within interval between 23-42 months and 
late if > 42 months. Women meeting within interval were considered compliant. Women not 
attending follow-up were classified as non-attenders. Women meeting too early, too late or 
not attending were considered non-compliant. 
 
In both cohorts, 42 months (3.5 years) of follow-up after index were set as threshold for 
determination of most severe outcome in the first follow-up round (first screening round). 42 
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months to 78 months of follow-up (6.5 years from index) was considered the second 
screening round.  
 
2.7 Statistics 
All statistical analyses were done using IBM SPSS Statistics, version 24.0 and included chi-
square, survival analysis and Cox-regression. Due to small numbers of study participants 
beyond 81 months of observation, we stopped survival analyses at 81 months, making 78 




The Regional Committee for Medical and Health Research Ethics, North Norway, has 
evaluated the protocol as a quality assurance study fulfilling the requirements for data 
protection procedures within the department (2011/2605/REK Nord). Norwegian regulations 
exempt quality assurance studies from written informed consent from the patients. The Patient 






3.1 Inclusion, exclusion and cohort characteristics 
3,089 women had an ASC-US/LSIL inclusion cytology and 850 women an ASC-H/HSIL 
inclusion cytology. Table 1 illustrates the exposed cohort and control cohort selection 
according to the inclusion- and exclusion criteria. In total, 2,864 ASC-US/LSIL women and 
701 ASC-H/HSIL women were excluded, leaving an exposed cohort of 374 women having 
histologically confirmed normal (59.1%) and CIN1 (40.9%) (p < 0.01). 31,335 women had a 
normal inclusion cytology, and 5,387 women were excluded, leaving a control cohort of 
25,948 women.  
 
Table 2 illustrates the exposed cohort and control cohort characteristics. The age was evenly 
distributed within the control cohort. Women in the exposed cohort were significantly 
younger, where 55.1% were aged 25-39 years. More women in the exposed cohort had no 
screening history (15.2%) or had an ASC-US/LSIL cytology (7.2%) before inclusion 
compared to the control cohort (6.9% and 1.6%, respectively).  
 
3.2 Compliance to first follow-up after index 
There were significant differences between cohorts regarding compliance to first follow-up 
after index (Table 3). Most women in the exposed cohort (69.5%) were compliant compared 
to 42.2% in the control cohort. 5.3% of women in the exposed cohort and 14.4% of women in 
the control cohort did not attend further follow-up. There were no obvious differences in 
compliance by age groups. 
 
3.3 First and second screening round 
The worst histological diagnose at 42 and 78 months by cohort is illustrated in Table 4. The 
CIN2+ fractions in the exposed cohort at 42 and 78 months were almost ten-fold compared to 
the control cohort. 
 
By 42 months, the proportions of women that returned to screening were 69.0% in the 
exposed cohort and 46.1% in the control cohort. 17.6% of women in the exposed cohort and 
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38.8% of women in the control cohort had an incomplete follow-up (cytological abnormalities 
in follow-up, but not yet solved). By 78 months, the proportions of women that returned to 
screening were 56.7% in the exposed cohort and 42.4% in the control cohort. In the same 
order, 27.3% and 42.3% had an incomplete follow-up. 
 
3.4 Cervical cancer 
At 42 months, 8 cases of cervical cancer (3 squamous cell carcinomas and 5 
adenocarcinomas) occurred in the control cohort only. At 78 months, 1 woman (0.3%) in the 
exposed cohort and additionally 11 women in the control cohort had developed cervical 
cancer, of which 8 cases (including the case among exposed cohorts) were squamous cell 
carcinomas and 4 cases were adenocarcinomas. (Table 4) The median time to diagnosis 
among women developing cervical cancer was 53.5 months (range 3-76). Five cases were 
classified as FIGO-stage Ia, 6 were Ib and one was stage IV. 
 
The exposed woman that developed squamous cell carcinoma had an inclusion cytology of 
ASC-H/HSIL. She was compliant and was followed-up according to guidelines at scheduled 
intervals with subsequent normal cytologies and had a histological examination after three 
subsequent ASC-US/LSIL cytologies. The cancer diagnose was set 76 months of follow-up 
after index and was FIGO-staged Ia. 
 
3.5 HPV-status before index  
Table 5 shows the HPV-status before index by screening status at 78 months in the exposed 
cohort. 197 of 374 women (52.7%) had no HPV-result. Of women with an HPV-test, 149 of 
177 (84.2%) were HPV-positive, of which 21 (of 40 in total) women had CIN2+ at 78 
months. 28 of 177 (15.8%) were HPV-negative, of which 2 women had CIN2+ at 78 months. 
The only case of squamous cell carcinoma in the exposed cohort had no HPV-result before 
index.  
 
3.6 Cumulative incidence of CIN2+ and CIN3+  
At the first follow-up visit, 227 women had a normal cytology or histology and 147 women 
had an abnormal cytology (inadequate or ASC-US+). Table 6 shows the cumulative 
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incidences of CIN2+ and CIN3+ with 95% confidence intervals for the exposed cohort 
stratified by the first follow-up cytology, and the control cohort.  
 
Figure 2 shows the cumulative incidence of CIN2+ plotted by follow-up in months after 
index. The cumulative incidence of CIN2+ at 42 and 78 months was significantly higher 
among exposed cohort women having an abnormal follow-up cytology (17.9% and 22.0%) 
compared to exposed cohort women having a normal follow-up cytology (7.1% and 11.9%). 
In the exposed cohort, both follow-up outcomes had significantly higher cumulative 
incidences of CIN2+ compared to the control cohort (0.43% and 1.4%). 
 
Figure 3 shows the cumulative incidence of CIN3+ plotted by follow-up in months after 
index. The cumulative incidence of CIN3+ at 42 and 78 months was significantly higher 
among exposed cohort women having an abnormal follow-up cytology (8.5% and 9.8%) 
compared to exposed cohort women having a normal follow-up cytology (2.5% and 5.2%). In 
the exposed cohort, both follow-up outcomes had significantly higher cumulative incidences 
of CIN3+ compared to the control cohort (0.24% and 0.73%). 
 
Cumulative incidences by most recent cytology or normal histology results before inclusion 
were not statistically significant for any outcome. 
 
3.7 Age-stratified cumulative incidence of CIN2+ and CIN3+ 
The age-stratified (women aged ≥ 40 or < 40 years) cumulative incidences of CIN2+ are 
illustrated in figure 4. All age-specific exposed cohorts had significantly higher cumulative 
incidences of CIN2+ compared to the age-specific control cohorts. The cumulative incidence 
of CIN2+ was significantly higher for younger women in the control cohort compared to older 
women. The cumulative incidence of CIN2+ was significantly higher for younger women in 
the exposed cohort with an abnormal follow-up compared to younger women in the exposed 
cohort with a normal follow-up. Within exposed cohort follow-up results, the cumulative 
incidence of CIN2+ was independent of age. 
 
The age-stratified (women aged ≥ 40 or < 40 years) cumulative incidences of CIN3+ are 
illustrated in figure 5. The cumulative incidence of CIN3+ was significantly higher for the 
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younger women in the control cohort compared to older women. Within exposed cohort 
follow-up results, the cumulative incidence of CIN3+ was independent of age.  
 
3.8 Hazard ratio 
Table 7 shows the age-adjusted hazard ratio (HR) for CIN2+ and CIN3+ with 95% confidence 
intervals. The risk for developing CIN2+ was significantly higher for exposed cohort women 
having an abnormal first follow-up cytology (HR 22.5) than exposed cohort women having a 
normal first follow-up cytology (HR 9.0) using the control cohort as reference. The increased 
risk for developing CIN2+ was highly significant among women aged 25-39 years (HR 6.1) 
compared to women aged 55-69 years. The age-adjusted HR for CIN3+ showed the same 
trend, where women in the exposed cohort with an abnormal follow-up had significantly 
higher risk (HR 17.1) than women in the exposed cohort with a normal follow-up (HR 6.8) 
using the control cohort as reference. Women aged 25-39 years also had significantly higher 








4.1 Important findings 
Compliance to follow-up was better among women in the exposed cohort than women in the 
control cohort. The fact that few exposed women were lost to follow-up and about 70% were 
compliant, is possibly explained by different follow-up practices between groups. The 
exposed women were probably provided information by their physician or gynecologist and 
were aware of their increased cancer risk, compared to women in the control cohort that 
should rescreen in three years.  
 
The cumulative incidences of CIN2+ and CIN3+ were significantly higher among women in 
the exposed cohort having their first follow-up cytology being abnormal compared to normal. 
The risks for CIN2+ in both follow-up outcomes were significantly higher compared to the 
control cohort. Age-stratified cumulative incidences of CIN2+ and CIN3+ showed no 
significant differences within the exposed cohort follow-up outcomes, but younger women 
had significantly higher cumulative incidences of both CIN2+ and CIN3+ within the control 
cohort. Age-adjusted hazard ratios showed significantly higher risks for both CIN2+ and 
CIN3+ among women in the exposed cohort, using the control cohort as reference. Women 
aged 25-39 years had significantly higher risk for CIN2+ and CIN3+ compared to women 
aged 55-69 years.  
 
Within the exposed cohort, the 95% confidence intervals for cumulative incidences 
overlapped, both between screening rounds and age-stratified, meaning there was no 
significant differences in risk increase between screening rounds or by age. However, the 
results showed an increasing trend between screening rounds. The 95% confidence intervals 
for age-adjusted HR’s also overlapped, meaning the HR between abnormal and normal 
follow-up cytologies were not significantly different. The 95 % confidence intervals of HR’s 
on CIN2+ and CIN3+ between age groups were narrow and not overlapping, and thus the 
differences were significant. 
 
We initially wanted to assess CIN2+ risks in follow-up of women having histologically 
confirmed normal/CIN1 by cytology and HPV-testing alone or in combination, and by that 
apply the concept of risk stratification to our study population. Of all 53,220 women screened 
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in our background population between 2006 to 2011, the control cohort only resembled 0.7%. 
Because small numbers of exposed women and no uniform HPV-testing in follow-up, the risk 
calculations by multiple follow-up test results were not possible. However, we were able to 
calculate cumulative incidences in the exposed cohort stratified by the first follow-up 
cytology being normal or abnormal.  
 
The cumulative incidence of CIN2+ at 42 months was significantly higher for exposed 
women having an abnormal follow-up (17.9%, 95% CI: 11.6-24.2) compared to women 
having a normal follow-up (7.1%, 95% CI: 2.7-11.5). The cumulative incidence of CIN3+ 
was, in the same order, 8.5% (95% CI: 3.8-13.2) and 2.5% (95% CI: 0.0-5.2). Using the 
concept of risk stratification on CIN3+ risks presented by Castle et. al. (11), women having a 
normal cytology at the first follow-up after normal/CIN1 are close to the 3-year screening 
threshold of 2%. Having an abnormal cytology, the cumulative incidence of CIN3+ is 
consistent to follow-up within one year. The highly statistical uncertainty of our results, 
provides no basis for direct recommendations, but suggests that by adding HPV-testing to the 
first follow-up, a negative co-test could provide lower CIN3+ risks consistent to a safe return 
to screening within three years.  
 
The cumulative incidence of CIN3+ was in the control cohort 0.24% and 0.73% at 42 and 78 
months, respectively. The 95% confidence intervals were narrow, did not overlap and 
provided high statistical power. The cumulative incidence of CIN3+ was under 2%, still at 78 
months, consistent to rescreening in three years, as already practiced.  
 
The age-stratified cumulative incidence of CIN2+ and CIN3+ was significantly higher for 
women aged < 40 years in the control cohort compared to women aged ≥ 40 years, suggesting 
that most CIN2+ occur among younger women. By first follow-up cytology, in the age-span < 
40 years, exposed women having an abnormal cytology had a significantly higher cumulative 
incidence of CIN2+ than exposed women having a normal cytology. As there were no 
differences in cumulative incidences among women having abnormal or normal cytologies at 
first follow-up by age, the slope of the curves may indicate that abnormal cytologies were 
expressions of persistent HPV-infections. 
 
Women aged 25-39 years had significantly higher risks for progression to both CIN2+ and 
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CIN3+ compared to women aged 55-69 years, suggesting that younger women should be 
followed up more closely that older women.  
 
The proportion of women who had an incomplete follow-up at both 42 and 78 months were 
higher in the control cohort, but also increased during follow-up of the exposed cohort, 
suggesting that high numbers of women underwent follow-up for unsolved cytologies over 
long time. 
 
55.1% of women in the exposed cohort were aged 25-39 years. The prevalence of HPV-
infections has been reported as higher in younger age groups (34), suggesting that most low-
grade and undetermined cytological abnormalities occur among younger women. This 
probably explain the higher proportion of exposed women with no previous screening data 
that participate in screening for the first time. 
 
4.2 Results compared to relevant literature 
There are few studies examining CIN2+ risks in follow-up of histologically confirmed 
normal/CIN1 in a screening scenario. Most studies are performed as case-series on normal 
histology, CIN1 and/or normal colposcopy without biopsy as part of larger and organized 
cohort studies (e.g. the ALTS) with objectives deviating from ours.  
 
The cumulative incidences of CIN2+ provided by our study were much higher compared to 
Katki. et. al. (17) that reported 5-year CIN2+ risks of 2% and lower. The risks were provided 
by negative co-tests in follow-up of women having HPV-positive ASC-US and ASC-H/HSIL 
and subsequent histologically confirmed normal/CIN1 or normal colposcopy without biopsy. 
The study was performed on the Kaiser Permanente Northern California (KPNC) population, 
a well-screened American population with historically below-average cancer risks. (12) The 
inclusion- and exclusion criteria were relatively the same compared to our study, but they did 
not exclude women having histories of high-grade cervical lesions and women over 70 years. 
They also included women not having histologically confirmed results. The study population 
of 20,319 women was much larger than ours, making calculations on specific follow-up 
managements possible. Their follow-up guidelines after histologically normal/CIN1 included 
co-testing, but they did not specify at which intervals. They only followed up women with 
negative co-tests compared to our study where women were stratified by only one follow-up 
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cytology of normal or abnormal. The 5-year CIN2+ risks were benchmarked to implicit risk 
thresholds for management, based- and developed on research on the KPNC population (12). 
 
The 2-year CIN2/3 risk, presented by Guido et. al. (32) of 9.8% (HPV-positive ASC-US) and 
11.3% (LSIL) was not stratified by any follow-up result. This study was part of a larger study 
designed to evaluate management (triage, conservative management, immediate colposcopy) 
of ASC-US and LSIL cytologies in primary screening (not HSIL). Since this subset of women 
was derived from the ALTS immediate colposcopy arm, the time to further examination and 
resolution probably was shorter and increased the risk of detection bias. Additionally, the 
post-histology follow-up was at 6, 12, 18 and 24 months with cytology, HPV-test and 
cervigram, and was much more thorough and organized compared to our population. All 
ASC-US were HPV-positive at inclusion, which probably increased the probability to find 
CIN2+ compared to our study population that was only included by cytology results.  
 
Mittal et. al. (33) assessed the CIN2+ risk in follow-up of high-risk HPV (HR-HPV) positive 
women having histologically confirmed normal/CIN1 in a public screening demonstration 
project in rural areas in India. 6.3% of study participants progressed to CIN2+ and the highest 
fraction progressing were aged 50-60 years, which is opposite of our findings. All women 
were HR-HPV-positive, being the only inclusion criteria, which is not comparable to ours that 
comprised cytology results in primary screening, only. As of our study, they excluded women 
having history of any CIN. They found HPV-persistence to be the only significant factor for 
progression. This study was performed as a demonstration project in a rural population not 
previously screened which may explain the high fraction of older women progressing to 
CIN2+. The follow-up was organized yearly, by HR-HPV-testing, colposcopy and biopsy. 
Only 48.8% had at least one follow-up visit, despite actively reminding and even look up non-
attending study participants.  
 
Thus, our results cannot directly compare to other studies hence to differences in study 
objective, populations, study design and follow-up. 
 
4.3 The natural course of an HPV-infection 
The HPV-infection natural course is of relevance to our exposed cohort. The inclusion 
cytology of ASC-US/LSIL or ASC-H/HSIL indicated an HPV-infection. Our exposed cohort 
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comprised women having normal or low-grade histology results that most likely resembled an 
HPV-infection cleared or in regress, regardless if the lesion was true or missed during 
colposcopy and biopsy. The mean HPV-infection duration of 6-18 months (5) equaled time 
from primary screening to completed triage, enabling the infection to regress.  
 
HPV-test coverage in the exposed cohort was low (47.3%). 149 of 177 (84.2%) women with a 
valid HPV-result, were HPV-positive. Considering our exposed cohort comprising women 
both having ASC-US/LSIL (eligible for triage with HPV-test and cytology) and ASC-H/HSIL 
(eligible for immediate colposcopy/biopsy) inclusion cytologies, the result was expected since 
ASC-H/HSIL women were not recommended an HPV-test. If excluding ASC-H/HSIL 
women, the HPV-test coverage was close to adequate (74.7%) during ASC-US/LSIL triage. 
Among women having ASC-US/LSIL inclusion, 63.1% were HPV-positive, which was 
expected since the HPV-positive triage test qualified for colposcopy and biopsy. 
 
More exposed women (7.2%) had an antecedent ASC-US/LSIL cytology prior to inclusion 
compared to women in the control cohort (1.6%), indicating that the HPV-infection started 
before inclusion, and the inclusion cytology simultaneously was part of a follow-up. At some 
point of follow-up after histologically confirmed normal/CIN1, the HPV-infection or 
histological lesion should be suspected as persistent or providing high risk for progressing to 
CIN2+. As previously mentioned, large proportions of women in our study had incomplete 
follow-up without any histologically confirmed diagnose at 78 months, leaving the actual 
proportion of women progressing or having persistent infections unknown. Incomplete 
follow-up is little discussed in previous publications.  
 
HPV-persistence (33) and type-specific HPV-infections (28) are associated with progression 
to CIN2+/CIN3 and taking into account that few CIN1 progress within the first year after 
detection (27, 28), a follow-up test with high specificity could be favorable. We did not have 
enough data to look upon HPV- or histology persistence in our exposed cohort, but other 
studies have examined both test characteristics in normal/CIN1 follow-up (29) and treatment 
of persistent CIN1 (35). 
 
Sørbye et. al. (29) compared test characteristics of cytology and HPV E6/E7 mRNA-testing in 
follow-up after histologically confirmed normal/CIN1 in the same background population as 
ours. The HPV mRNA-test compared to cytology with cutoff ASC-US+ was as sensitive 
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(89.1% and 84.1%, respectively), but more specific (92.5% and 76.4%, respectively) for 
CIN2+. The HPV mRNA test also had higher positive predictive value (PPV) than cytology 
with cutoff ASC-US+ (78.8% and 52.8%, respectively). The results show that a negative HPV 
E6/E7 mRNA-test would identify most cases having low risk for progression to CIN2+ in 
follow-up of women having histologically confirmed normal/CIN1. Compared to our study, 
the background population is the same, but Sørbye et. al. did not exclude women having a 
history of high-grade cytological- and histological cervical lesions. However, despite some 
differences in study design, the results are probably applicable to our study population. 
 
Spinillo et. al. (35) assessed the cumulative CIN2+ risks in an Italian screening population 
having persistent CIN1 (>2 years), treated with Loop Electrosurgical Excision Procedure 
(LEEP).  The cumulative incidence of CIN2+ was, after 2 and 3 years of follow-up with 
cytology, colposcopy and molecular diagnostics after six months, 1 year and thereafter every 
year, 2.3% and 5.5%, respectively. Persisting- and HR-HPV-infection in follow-up were 
associated with higher rate of CIN persistence/progression and all cases of CIN2+ had 
cytological abnormalities during follow-up. (35) The CIN3+ risks in this publication were not 
calculated, but considering the CIN3+ risks usually being lower than CIN2+ risks, the post-
treatment risks were probably closely consistent to a prolonged screening interval. 
 
4.4 Strengths of the study 
This study is population-based in a country having had a well-organized screening 
programme for over 20 years. When selecting the study population, we excluded women 
having history of high-grade cytology and/or CIN that represented persistent HPV-infections, 
leaving a subset of low-risk women being exposed- or not exposed to a probable incident 
HPV-infection. 
 
We tried to avoid selection bias by defining the inclusion cytology as the first cytology within 
the inclusion period. E.g. to avoid extracting cases from the control cohort, making it seem 
healthier. If a woman had an HSIL cytology after a normal cytology within the inclusion 
period, the normal cytology had priority in cohort allocation. We tried to avoid observation 




4.5 Limitations and weaknesses of the study  
Detection bias is a consequence of our study design. The historical and register-based data 
provides limited information. We don’t know how assessments were made, how the clinicians 
interpreted results and what reasons that determined further management (could explain not-
indicated CIN2+ and high number of follow-up visits before being solved). The exposed 
cohort and the control cohort represent women having different recommendations of follow-
up. Therefore, high- and low-grade lesions will be over-detected in the exposed cohort. 
Differences in compliance also contributes to detection bias among the exposed and non-
exposed cohort.  
 
The low number of women in our exposed cohort provided low statistical power and wide, 
overlapping confidence intervals. 
 
4.6 Implication of findings 
The background characteristics and CIN2+ risks probably vary between populations. Katki et. 
al. (12) suggested the concept of benchmarking to be generalizable to other populations, only 
requiring the risks for equal management to be the same within the population to which they 
are being applied. A study with this objective, calculating CIN3+ risks on cytology or other 
follow-up practices on our population would be advantageous for benchmarking co-test 
outcomes for different subsets of women.  
 
Future clinical trials with organized co-testing after histologically confirmed normal/CIN1 
would be favorable because of limitations to the registry-based study design. Introduction 
HPV-testing in primary screening, knowing the HPV-status both before and after the 
normal/CIN1 histology, the HPV-infection course would classify as either persistent or 
regressed, making future studies easier to perform as registry-based. 
 
Younger women are, both after histologically confirmed normal/CIN1 and primary screening, 
under increased risks for developing both CIN2+ and CIN3+, and should be followed up 
closer than older women. Women having histologically confirmed normal/CIN1 resemble a 
small part of the total screening population, suggesting that closer follow-up would not 




A high proportion of women undergo unsolved follow-up over long time. It is a challenge for 
the health care system that almost 30% of women in the exposed cohort and nearly 40% of 
women in the control cohort were still unsolved after 78 months. This suggest that high 
proportions of women undergo unnecessary follow-up, probably inducing psychological 
distress and decreased trust to the screening programme. Early intervention with vaporization 
or diagnostic conization are suggestions to avoid unnecessary follow-up. Using follow-up 





Compliance to guidelines was better among women attending follow-up after histologically 
confirmed normal/CIN1 compared to women having normal cytologies in primary screening.  
 
Women in follow-up after histologically confirmed normal/CIN1 were under higher CIN2+ 
risks compared to women having normal cytologies in primary screening. By the first follow-
up cytology after normal/CIN1, the cumulative incidence of CIN2+ was significantly higher 
for women having an abnormal cytology compared to a normal cytology Women aged 25-39 
years were under higher risks for CIN2+ than older women, and should be followed up 
closely. 
 
For women that had a normal cytology at the first follow-up after histologically confirmed 
normal/CIN1, the cumulative incidence of CIN3+ was closely consistent to screening in three 
years. A negative co-test at the first follow-up after histologically confirmed normal/CIN1 
probably provides a risk consistent to safe return to screening within a three-year interval. 
 
Improving the assessment of HPV-persistence by future HPV-testing in primary screening, 
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7 Tables and figures 
 













N n n N n N 
31,335  Inclusion cytology  3,089  850 
 1,914 Age ≤ 24 years 613  41  
 1,268 Age ≥ 70 years 49  76  
 591 ≥ HSIL history  64  36  
 343 ≥ CIN 1 history  43  13  
 1,271 ≥ HSIL before/≥ CIN 1 history 101  53  
 5,387 Excluded 870  219  
25,948  Eligible for study participation  2,219  631 
  Missing follow-up 107  15  
  Incomplete follow-up* 159  36  
  Back to screening 1,499  57  
  CIN2 not indicated** 9  11  
  CIN3 not indicated** 15  11  
  CIN2 indicated 128  157  
  CIN3 indicated 77  186  
  CC not indicated 0  0  
  CC indicated 0  9  
 0 Excluded 1,994  482  
  Normal/CIN1 histology  225  149 
25,948 Total included (index) 379 
  
* Follow-up not according to management guidelines or case unsolved 


















2006-2008 25,948 (100) 169 (45.2) 26,117 (99.2) 14,334.5 
p < 0.01 2009-2011 0 (0) 205 (54.8) 205 (0.8) 
Total 25,948  374 26,322  
Age 
25-39 9,369 (36.1) 206 (55.1) 9,575 (36.4) 
65.1 
p < 0.01 40-54 9,485 (36.6) 116 (31.0) 9,601 (36.5) 
55-69 7,094 (27.3) 52 (13.9) 7,146 (27.1) 




No screening history 1,794 (6.9) 57 (15.2) 1,851 (7.0) 
133.1 
p < 0.01 
 
Unsatisfactory 865 (3.3) 17 (4.5) 882 (3.4) 
Normal 22,282 (85.9) 266 (71.1) 22,548 (85.7) 
ASC-US/LSIL 420 (1.6) 27 (7.2) 447 (1.7) 
Normal histology 587 (2.3) 7 (1.9) 594 (2.3) 


















Non-attenders 3,727 (14.4) Non-attenders 20 (5.3) 3,747 (14.2) 
Early 
<12 mo.* 1,709 (6.6) Interval <12 mo. 260 (69.5) 1,969 (7.5) 
12-23 mo. 2,640 (10.2) 
Late 
12-23 mo. 62 (16.6) 2,702 (10.3) 
Interval 24-42 mo. 10,959 (42.2) 24-42 mo. 25 (6.7) 10,984 (41.7) 
Late 
43-59 mo. 6,243 (24.1) 43-59 mo. 7 (1.7) 6,250 (23.7) 
80-107 
mo. 670 (2.6) 
80-107 
mo. 0 670 (2.5) 
Total 25,498 Total 374 26,322 (100) 





Table 4 Worst histological diagnose at 42 months (first screening round) and 78 









42 mo. 78 mo. 42 mo. 78 mo. 
CIN2 110 (0.4) 109 (0.4) 21 (5.6) 23 (6.1) 
CIN3 77 (0.3) 113 (0.4) 9 (2.4) 16 (4.3) 
SCC* 3 (0.0) 7 (0.0) 0 1 (0.3) 
AC** 5 (0.0) 4 (0.0) 0 0 
CIN2+ 195 (0.8) 233 (0.9) 30 (8.0) 40 (10.7) 
 
*SCC = Squamous cell carcinoma 






Table 5 Exposed cohort HPV-status before index and screening status at 78 months  
 
* CC = 1 case of squamous cell carcinoma 
** % column 
  
Screening status at 
78 months 
Exposed cohort HPV-status before index 
n (%**) 
Missing Negative Positive 
Not attending 9 (4.6) 1 (3.6) 10 (6.7) 
Back to screening 122 (61.9) 17 (60.7) 73 (49.0) 
Incomplete f-up 49 (24.9) 8 (28.6) 45 (30.2) 
CIN2 9 (4.6) 2 (7.1) 12 (8.1) 
CIN3 7 (3.6) 0 9 (6.0) 
CC* 1 (0.5) 0 0 
Total N = 379 197 28 149 
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Table 6 Cumulative incidence of CIN2+ and CIN3+ at 42 and 78 months of follow-up 
after index 
Cohort Follow-up length 





42 mo. 0.43 (0.34-0.52) 
78 mo. 1.4 (1.2-1.6) 
Exposed  
normal cytology 
42 mo. 7.1 (2.7-11.5) 
78 mo. 11.9 (4.1-19.7) 
Exposed  
abnormal cytology 
42 mo. 17.9 (11.6-24.2) 
78 mo. 22.0 (14.4-29.6) 
Cohort Follow-up length 





42 mo. 0.24 (0.16-0.32) 
78 mo. 0.73 (0.60-0.86) 
Exposed  
normal cytology 
42 mo. 2.5 (0.0-5.2) 
78 mo. 5.2 (0.0-11.1) 
Exposed  
abnormal cytology 
42 mo. 8.5 (3.8-13.2) 
78 mo. 9.8 (4.5-15.1) 
 
* Overall comparison, Wilcoxon (Gehan) statistic = 559.4 (p < 0.01) 




Table 7 Age-adjusted hazard ratio of CIN2+ and CIN3+ at 78 months of follow-up 
after index 
Cohort CIN2+ Hazard ratio 95% confidence interval 
Control 1 (ref)  
Exposed cohort f-up   
Normal 9.0* (4.8-17.0) 
Abnormal 22.5* (15.3-33.2) 
Age   
55-69 1 (ref)  
40-54 1.8 (1.1-3.0) 
25-39 6.1 (3.8-9.6) 
Cohort CIN3+ Hazard ratio 95% confidence interval 
Control 1 (ref)  
Exposed cohort f-up   
Normal 6.8* (2.5-18.3) 
Abnormal 17.1* (9.6-30.6) 
Age   
55-69 1 (ref)  
40-54 1.6 (0.7-3.7) 














Figure 2 Cumulative incidence of CIN2+ by months of follow-up after index for the 
exposed cohort of women with a normal follow-up cytology (green), abnormal follow-




Figure 3  Cumulative incidence of CIN3+ by months of follow-up after index for the 
exposed cohort of women with a normal follow-up cytology (green), abnormal follow-




Figure 4 Age-stratified cumulative incidence of CIN2+ for the exposed cohort of 
women with a normal follow-up cytology (Exp_N), an abnormal follow-up cytology 





Figure 5 Age-stratified cumulative incidence of CIN3+ for the exposed cohort of 
women with a normal follow-up cytology (Exp_N), an abnormal follow-upcytology 
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Design: Pasientserier 
Dokumentasjonsnivå  III 
Grade:  Lav 
Formål Materiale og metode Resultater Diskusjon/kommentarer 
Å introdusere kotesting 
i retningslinjene for 
screening i henhold til 
prinsippet ”lik 
håndtering av lik risiko”. 
I praksis brukes 
implisitte risikogrenser 




CIN3+ risiko ved kotest 
for å bestemme hvilke 
resultatkombinasjoner 
som behøver hvilken 
oppfølging. 
Data: Kaiser Permanente Northern 
California (KPNC) cohort 
 
Eksklusjon: 
• Alder under 30 og over 65  
• Ukjent Pap-resultat (1,1%) 
 
Inklusjon (studiepopulasjon): 
Kvinner 30-64 år som kotestes ved 
KPNC. (N=965 360) 
 
Oppfølging: for ASC-US/HPV+ 
gjøres HPV triage, nesten alltid 
kotest ved alder over 30. 
 
Biopsi- og kreftinformasjon samlet 
t.o.m. 31. desember 2010. Matchet 
med Bay Area Cancer Registry for 
å idendifisere alle caser, inkludert 
kvinner ikke lenger med i KPNC. 
 
Deretter beregnet implisitt 
risikogrense for Pap-test alene og 




5-års risiko for CIN3+, 
anbefalinger: 
• > 5.2 % Æ kolposkopi 
• Ca. 2.6 % Æ ny test innen 6-
12 mnd.  
• Rundt 0.26% Æ Ny test om tre 
år 
 
CIN3+ risiko ved kotestrestultater sammenlignet med risikogrenser (basert på Pap-











5-års CIN3+ risiko ved 
baseline Pap (uavh. HPV) 
 
 





































































6-12 mnd.  






3 år screen Pap- 95.6 0.26 HPV-/ASC-US 1.8 0.43 
5 år screen    HPV-/Pap- 92.0 0.08 
 
Beregning av CIN2+ risiko finnes også i artikkelen. 
Sjekkliste:  
• Var studien basert på et tilfeldig 
utvalg fra en egnet pasientgruppe? 
Nei  
• Var det sikret at utvalget ikke var 
selektert? Usikkert 
• Var inklusjonskriteriene for utvalget 
klart definert? Ja  
• Er svarprosenten høy nok? Ikke 
spesifisert. 
• Var alle pasientene i utvalget i 
samme stadium av sykdom? Ja 
• Var oppfølgningen tilstrekkelig 
(type/omfang/tid) for å synliggjøre 
endepunktene? Ikke spesifisert 
• Ble objektive kriterier benyttet for å 
vurdere/validere endepunktene? 
Ja 
• Ved sammenlikninger av 
pasientserier, er seriene 
tilstrekkelig beskrevet og 
prognostiske faktorers fordeling 
beskrevet? Ja 
• Var registreringen av data 

















CIN3+ risiko ved kotest 
med implisitte 
risikoterskler basert på 
Pap-resultater alene 
kan, på bakgrunn av 
”lik håndtering av lik 
risiko”, brukes til å 
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Beregne CIN2+ risiko 




med negative tester 
(HPV/cyt/kotest) som 
gir lav nok CIN2+ risiko 
forenlig med å utføre 
neste oppfølging 
innenfor et lengre 
intervall. 
 




• HPV+/ASC-US or LSIL+ Æ kolposkopi 
og biopsi 
• Normal/CIN1 oppfølging Æ kotesting, 
intervaller ikke spesifisert 
 
Inklusjon: Kvinner >25 år ved baseline med 
cytologi eller kotest som indikerer kolposkopi. 
Screenet mellom 2003-2010. (N=36801) 
 
Eksklusjon:  
• Ingen flere oppfølgingsdata (n=11759) 
• CIN2+ biopsi (n=4177) 
• Behandlet for <CIN2 (n=335) 
• Tvetydige utfall (n=103) 
• Mangler oppfølging, HPV- og 
cytologidata (n=108) 
 
Studiepopulasjon: Normal/CIN1 biopsi eller 
antatt normal kolposkopi uten biopsi. 
(N=20319) 
 
Follow-up: KPNC retningslinjer. Histologisk 
utfall registrert t.o.m. 31. desember 2010.  
 
Beregninger: 





… hvorav 5-års CIN2+ risiko ble beregnet 
blant kvinner med negative 
oppfølgingsprøver i alle kategoriene.  
 
Tabell 3   5-års CIN2+ risiko hvis HPV+/ASC-US eller LSIL før biopsi, fremstilt mot klinisk 
risikoterskel som brukes for å bestemme oppfølging 

















































4.0     
Intermediær    1 negativ 2 negative 
2.0 
1.8   
3 år ny 





















































4.4   
Intermediær  1 negativ kotest 2.2 1 negativ cyt 1.7 
3-y return Cyt-: 0.68   1 negativ HPV 0.58 
 
 
 Sjekkliste:   
• Var studien basert på et tilfeldig 
utvalg fra en egnet 
pasientgruppe? Nei 
• Var det sikret at utvalget ikke er 
for selektert? Usikkert 
• Var inklusjonskriteriene for 
utvalget klart definert? Ja 
• Er svarprosenten høy nok? 
Ikke beskrevet 
• Var alle pasientene i utvalget i 
samme stadium av sykdom? Ja 
• Var oppfølgningen tilstrekkelig 
(type/omfang/tid) for å 
synliggjøre endepunktene? Ja 
• Ble objektive kriterier benyttet 
for å vurdere/validere 
endepunktene? Ja 
• Ved sammenlikninger av 
pasientserier. Ikke relevant 











Ikke tatt hensyn til scr. historie.  
Ikke kontrollgruppe. 
Beskriver ikke frafall. 
15-40% uten biopsi mellom index og 
oppfølging.  
Muligens ikke overførbart til noen 





ga ikke lave nok CIN2+ 
risikoer forenlig med 
oppfølging etter fem år. 
 
For kvinner med HPV+ 
og ASC-US/LSIL før 
biopsien, gav én 
negativ kotest en 
CIN2+ risiko forenlig 
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Dokumentasjonsnivå  III 
Grade:  Lav 
Formål Materiale og metode Resultater Diskusjon/kommentarer 
Å sammenligne 
oppfølginger av kvinner 
henvist til 
kolposkopi/biopsi pga. 
LSIL eller HPV+/ASC-US, 
der resultatet var CIN1 
eller mindre. 
Bakgrunnspopulasjon: ASC-US LSIL 
triage study (ALTS) 
 
Inklusjon: 
Immediate colposcopy (IC)-arm: 
• HPV+/ASC-US (n=1132)  
• LSIL (n=852)  
 
Eksklusjon:  
• Conservative management (CM)-
arm av LSIL 
• Unormal kolposkopi, mangl. biopsi 
(n=42) 
• CIN2+ (n=355) 
• CIN2+ mellom initial og oppf. biopsi 
eller LEEP før dette (n=48) 
 
Studiepopulasjon: 
• CIN1 (HPV+/ASC-US) (n=881) 




6, 12 og 18 mnd med cyt, HPV, 
cervigram. 
HSIL henv. til kolposkopi. 
Exit undersøkelse ved 24 mnd. 
 
Endepunkt: 
Histologisk verifisert CIN2+. 
Table 1 Distribution of enrollment colposcopy and directed biopsy 
results by referral cytology group for study population and risk for 









CIN grade 2 





192 96 288 30 (10.4) 
Negative 
biopsy 338 203 541 53 (9.8) 
CIN1 351 359 710 80 (11.3) 
All 881 658 1539 163 (10.6) 
P=0.70 comparing percentage diagnosed with CIN grade 2 or 3 in three 
groups. *Risk for CIN2-3 detected either during 2-year follow-up or at exit 
colposcopy. 
Table 4 Performance of repeat cytology in post colposcopy management 
of women with CIN1 or less. 
Management strategy 
Sensitivity of detection 
of subsequent CIN 
grade 2 or 3 (% 
[95%CI]) 
Women who would be 
positive (% [95 % CI]) 















































• Var studien basert på et tilfeldig utvalg fra 
en egnet pasientgruppe? Ja 
• Var det sikret at utvalget ikke var 
selektert? Usikkert 
• Var inklusjonskriteriene for utvalget klart 
definert? Ja 
• Er svarprosenten høy nok? Ikke 
beskrevet frafall  
• Var alle pasientene i utvalget i samme 
stadium av sykdom? Ja 
• Var oppfølgningen tilstrekkelig 
(type/omfang/tid) for å synliggjøre 
endepunktene? Ja 
• Ble objektive kriterier benyttet for å 
vurdere/validere endepunktene? Ja 
• Ved sammenlikninger av pasientserier, er 
seriene tilstrekkelig beskrevet og 
prognostiske faktorers fordeling 
beskrevet? Ikke relevant 





Bakgrunnspopulasjonen er randomisert til ulike 




ALTS ikke designet for å se på oppfølging etter 
kolposkopi. Tatt ut noen kvinner med CIN2-3 på 
kvalitetskontroll, dermed friskgjøres 
studiepopulasjonen mtp. klinisk realitet. 
Risiko for detection bias pga direkte kolposkopi, 
ved exit visste klinikeren tidligere resultater. 
Konklusjon 
Den mest effektive 
testen for å 
identifisere CIN2-3 
etter kolposkopi, kan 
være HPV-test alene 
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Design: Pasientserie 
Dokumentasjonsnivå  III 
Grade:  Lav 
Formål Materiale og metode Resultater Diskusjon/kommentarer 








HR-HPV positive (HCII test) 
kvinner (n=2045) 
30-60 år offentlig 
screeningsdemonstrasjonsprosjekt 
av CNCI, Kolkata, India. 
CIN1/normal biopsi eller normal 




CIN2+ baseline, N= 220 
 
Oppfølging: 
HR-HPV, kolposkopi og biopsi 
årlig. 
Aktiv påminnelse og oppsøking av 





Analyser, risiko for CIN2+ 
påvirket av: 
- Baseline karakteristika 
- HPV viral load, HPV persistens 




46,8 % minst én oppfølging.  
Median oppfølgingstid 2,1 personår.  
 
Tabell 3. Karakteristika som påvirker progresjon til CIN2+. Ikke tatt med 





























































































































































Progresjon av CIN 1 hos 27/177 (15,3 %), eneste signifikant faktor var HPV 
persistens.  




- Var studien basert på et tilfeldig 
utvalg fra en egnet pasientgruppe? 
Rural area selektert ut fra 
gjennomførbarhet på prosjektet og 
lokale behov. 
- Var det sikret at utvalget ikke var 
selektert? Usikkert 
- Var inklusjonskriteriene for utvalget 
klart definert? Ja 
- Er svarprosenten høy nok? Nei 
- Var alle pasientene i utvalget i 
samme stadium av sykdom? Ja 
- Var oppfølgningen tilstrekkelig 
(type/omfang/tid) for å synliggjøre 
endepunktene? Ja 
- Ble objektive kriterier benyttet for å 
vurdere/validere endepunktene? Ja 
- Ved sammenlikninger av 
pasientserier, er seriene tilstrekkelig 
beskrevet og prognostiske faktorers 
fordeling beskrevet? Ikke relevant 




- Relevant for utfordringer i 
lavressurspopulasjon 
- Ekskludert historie med cervical 
intraepitelial neoplasi 
   
 Svakhet 
Selektert populasjon. Høyt frafall  
- Ift. egen oppgave: ikke-etablert 
screeningprogram i 
lavressurspopulasjon og inklusjon kun 
basert på HPV 
Konklusjon 
Ca. ¾ av HR-HPV+ 
og lavgradig 
histologi klarerer 
infeksjonen ila kort 
tid, derav lav CIN3+ 
risiko. 
 
Eldre kvinner og 
høy/økende viral 
load har høyere 
risiko for HPV-
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Design: Historisk Kasusserie 
Dokumentasjonsnivå  III 
Grade: Middels 
Formål Materiale og metode Resultater Diskusjon/kommentarer 
Undersøke om HPV E6/E7 
mRNA-testing er mer 
spesifikk enn 
oppfølgingscytologi uten 
tap av sensitivitet 
postdiagnostisk av kvinner 
med negativ biopsi 
Celleprøver fra screening, populasjon 
Troms og Finnmark. 2005-2009 63740 
celleprøver og 6027 biopsier fra kvinner 
25-69 år. 1484 med ASC-H, HSIL eller 
ASC-US/LSIL og positiv HPV mRNA. 
 
Eksklusjonskriterier: 
- kvinner uten biopsi 
- CIN2+ på første biopsi 
- flere unormale cyt. og/eller 
HPV+ på post-
kolposkopioppfølging, men uten 
rebiopsi 
 
520 kvinner med negativ/lavgradig biopsi 
inkludert. 192 tok en væskebasert 
cytologi for HPV mRNA-testing. 328 ble 
det mottatt vanlig Pap-smear der HPV-
testing ikke er mulig (cytologigruppe). 
 
CIN2+ brukt som endepunkt og CIN0-1 
som fravær av sykdom. ++ 
 
Sens, spes, PPV, NPV beregnet fra 2x2-
tabell for cytologi, HPV mRNA og begge. 
Cutoff ASC-US+ og ASC-H+. 
 
Diagnosene hentet fra SymPathy. 
Biopsier evaluert av erfarne patologer. 
 
Statistikk: 
- Pearson chi square for å 
undersøke assosiasjon mellom 
testresultat og endelig 
sykdomsstatus 
Cytologi (n=328): 
Utfall i cytologigruppe med cutoff ASC-US+ 
Cytologi 
Utfall  % 95% CI 
CIN2+ <CIN2 Total Sensitivitet 84.6 76.6, 92.6 
ASC-
US+ 66 59 125 Spesifisitet 76.4 
71.1, 
81.7 
NILM 12 191 203 PPV 52.8 44.0, 61.6 




Utfall  % 95% CI 
CIN2+ <CIN2 Total Sensitivitet 53.8 42.8, 64.9 
ASC-
US+ 42 9 51 Spesifisitet 96.4 
94.1, 
98.7 
NILM 36 241 277 PPV 82.4 71.9, 92.8 
Total 78 250 328 NPV 87.0 83.0, 91.0 
 
HPV mRNA (n=192): 




Utfall  % 95% CI 
CIN2+ <CIN2 Total Sensitivitet 89.1 80.1, 98.1 
Positiv 41 11 52 Spesifisitet 92.5 88.2, 96.7 
Negativ 5 135 140 PPV 78.8 67.7, 89.9 
Total 46 146 192 NPV 96.4 93.3, 99.5 
 
Ratio for sens, spes og PPV for HPV mRNA sammenlignet med cytologi hhv 1.05, 
1.21 og 1.49. 
 
Utfall for HPV mRNA-gruppe hvis triage med HPV mRNA kombinert med cytologi: 
- Cutoff ASC-US+ sens 97.8, spes 63.0, PPV 45.5, NPV 98.9. 
- Cutoff ASC-H+ sens 93.5, spes 89.0, PPV 72.9, NPV 97.7. 
 
 Sjekkliste: 
• Var studien basert på et tilfeldig utvalg 
fra en egnet pasientgruppe? Nei 
• Var det sikret at utvalget ikke var 
selektert? Usikkert 
• Var inklusjonskriteriene for utvalget 
klart definert? Ja 
• Er svarprosenten høy nok? Usikkert 
• Var alle pasientene i utvalget i samme 
stadium av sykdom? Ja 
• Var oppfølgningen tilstrekkelig 
(type/omfang/tid) for å synliggjøre 
endepunktene? Ja 
• Ble objektive kriterier benyttet for å 
vurdere/validere endepunktene? Ja 
• Ved sammenlikninger av 
pasientserier, er seriene tilstrekkelig 
beskrevet og prognostiske faktorers 
fordeling beskrevet? Ikke relevant 





 Stor studiepopulasjon 
 
 Svakhet 













mRNA-testing er like 




høyere PPV.  
Land 
Norge – Troms og 
Finnmark 





Spinillo A, Gardella B, Iacobone AD, Dominoni M, Cesari S, Alberizzi P. Outcome of Persistent Low-Grade Cervical 
Intraepithelial Neoplasia Treated With Loop Electrosurgical Excision Procedure. Journal of lower genital tract 
disease. 2016;20(4):307-11. 
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Dokumentasjonsnivå  III 
Grade:  Middels 
Formål Materiale og metode Resultater Diskusjon/kommentarer 
Å evaluere utfall av 
persistent (> 2 år) CIN1 
behandlet med loop 
electrosurgical excision 
procedure (LEEP). 
Bakgrunnspopulasjon: kvinner som var til 
kolposkopi i perioden 2007-2014 ved 
University of Pavia, IRCCS Fondazione 
Policlinico San Matteo, Pavia, Italia. 
 
Inklusjonskriterier (N=324): 
• CIN1 etter ASC-US/LSIL 
• Persistens av lavgradig cervixlesjon 
enten ved ASC-US/LSIL eller CIN1 ved 
minst 2 tilfeller under 2 år oppfølging. 
• Vellykket kolposkopi 




• Ikke utført LEEP (n=20) 
• Høygradig LEEP (n=22) 
• LEEP negativ for CIN (n=10) 
• Utilstrekkelig oppfølging (<1 år) (n=20) 
 
Studiepopulasjon: 
Persistent eller intermitterende CIN1 med 
minst 24 mnd varighet behandlet med LEEP 
(N=252) 
Persistens dokumentert ved: 
• 64.7 % ASC-US/LSIL x 2 
• 35.3 % cyt + biopsi 
 
Oppfølging: 
Cytologi, kolposkopi, molekylærdiagnostikk 6 
mnd, 1 år og deretter hvert år post-LEEP.  
Alle hadde minst ett år oppfølging. Median oppf. 
tid 25 mnd.  
69.8 % hadde minst 2 år oppfølging og 50.8 % 
hadde minst tre år. 
 
Alle tilfeller av CIN2+ hadde celleforandringer i 
oppfølgingen. 
 
Kumulativ insidens av CIN2+ 
• Ved 2 år: 2.3 % (4/276) 
• Ved 3 år: 5.5 % (7/128) 
 
Lavgradige cervixlesjoner post-LEEP 
diagnostisert hos 70 kvinner (27.8 %) 
 
Persisterende og høyrisiko HPV-infeksjon i 




• Var studien basert på et tilfeldig utvalg fra 
en egnet pasientgruppe? Nei 
• Var det sikret at utvalget ikke var 
selektert? Usikkert 
• Var inklusjonskriteriene for utvalget klart 
definert? Ja 
• Er svarprosenten høy nok? Ja 
• Var alle pasientene i utvalget i samme 
stadium av sykdom? Ja 
• Var oppfølgningen tilstrekkelig 
(type/omfang/tid) for å synliggjøre 
endepunktene? Ja 
• Ble objektive kriterier benyttet for å 
vurdere/validere endepunktene? Ja 
• Ved sammenlikninger av pasientserier, er 
seriene tilstrekkelig beskrevet og 
prognostiske faktorers fordeling 
beskrevet? Ikke relevant. 
• Var registreringen av data prospektiv? Ja 
 
 Styrke 
 Populasjonsbasert  
 Lite frafall   
 
  Svakhet 
 Ikke tatt hensyn til screeninghistorie 











US/LSIL cytologi.  
Andelen kvinner med 
lavgradige 
celleforandringer var 
fortsatt høy, med 10 
caser per 100 
personår ved 25 mnd 
median oppfølging.  
Land 
Italia 
År datainnsamling 
2007-2014 
